Circulating Levels and Dietary Intake of the Advanced Glycation End-product Marker Carboxymethyl Lysine in Chronic Kidney Disease Patients on Conservative Predialysis Therapy: A Pilot Study

Journal of Renal Nutrition

Volumn 21, Issue 4, 2011, Pages 329-339

  Piroddi, Marta ^a   Palazzetti, Ingrid ^a   Quintaliani, Giuseppe ^b   Pilolli, Francesca ^a   Montaldi, Massimiliano ^a   Valentina, Viola ^a   Libetta, Carmelo ^c   Galli, Francesco ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b S Maria Della Misericordia General Hospital   (Italy)

^c UNIVERSITY OF PAVIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ARGININE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; DRUG DERIVATIVE; INTERLEUKIN 6; LYSINE; N(6) CARBOXYMETHYLLYSINE; N(6)-CARBOXYMETHYLLYSINE; PENTOSIDINE;

AGED; ARTICLE; BLOOD; CALORIC INTAKE; CASE CONTROL STUDY; CHRONIC KIDNEY FAILURE; CROSS-SECTIONAL STUDY; DIET; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INFLAMMATION; MALE; MALNUTRITION; METABOLISM; MIDDLE AGED; NUTRITIONAL ASSESSMENT; PILOT STUDY; REGRESSION ANALYSIS; RENAL REPLACEMENT THERAPY; RISK FACTOR;

AGED; AGED, 80 AND OVER; ARGININE; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-SECTIONAL STUDIES; DIET; ENERGY INTAKE; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; INFLAMMATION; INTERLEUKIN-6; KIDNEY FAILURE, CHRONIC; LYSINE; MALE; MALNUTRITION; MIDDLE AGED; NUTRITION ASSESSMENT; PILOT PROJECTS; REGRESSION ANALYSIS; RENAL DIALYSIS; RISK FACTORS;

EID: 79959238921     PISSN: 10512276     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.jrn.2010.06.024     Document Type: Article

References (45)

1. Thorpe S.R., Baynes J.W. Maillard reaction products in tissue proteins: new products and new perspectives. Amino Acids 2003, 25:275-281.
2. Henle T. Protein-bound advanced glycation endproducts (AGEs) as bioactive amino acid derivatives in foods. Amino Acids 2005, 29:313-322.
3. Miyata T., Kurokawa K., van Ypersele de Strihou C Relevance of oxidative and carbonyl stress to long-term uremic complications. Kidney Int 2000, 76:S120-S125.
4. Thornalley P.J., Rabbani N. Highlights and hotspots of protein glycation in end-stage renal disease. Semin Dial 2009, 22:400-404.
5. Galli F. Protein damage and inflammation in uremia and dialysis patients. Nephrol Dial Transplant 2007, 22(Suppl 5):v20-v36.
6. Agalou S., Ahmed N., Babaei-Jadidi R., et al. Profound mishandling of protein glycation degradation products in uremia and dialysis. J Am Soc Nephrol 2005, 16:1471-1485.
7. Cohen B.D. Premature aging in uremia. Mol Cell Biochem 2007, 298:195-198.
8. Hartog J.W., de Vries A.P., Bakker S.J. Risk factors for chronic transplant dysfunction and cardiovascular disease are related to accumulation of advanced glycation end-products in renal transplant recipients. Nephrol Dial Transplant 2006, 21:2263-2269.
9. Taki K., Takayama F., Tsuruta Y., et al. Oxidative stress, advanced glycation end product, and coronary artery calcification in hemodialysis patients. Kidney Int 2006, 70:218-224.
10. Galli F., Benedetti S., Floridi A., et al. Glycoxidation and inflammatory markers in patients on treatment with PMMA-based protein-leaking dialyzers. Kidney Int 2005, 67:750-759.
11. Fragedaki E., Nebel M., Schupp N., et al. Genomic damage and circulating AGE levels in patients undergoing daily versus standard haemodialysis. Nephrol Dial Transplant 2005, 20:1936-1943.
12. Buetler T.M., Leclerc E., Baumeyer A., et al. N (epsilon)-carboxymethyllysine-modified proteins are unable to bind to RAGE and activate an inflammatory response. Mol Nutr Food Res 2008, 52:370-378.
13. Yan SF, Du Yan S, Ramasamy R, et al: Tempering the wrath of RAGE: an emerging therapeutic strategy against diabetic complications, neurodegeneration, and inflammation. Ann Med (in press).
14. Ahmed N., Thornalley P.J. Advanced glycation endproducts: what is their relevance to diabetic complications?. Diabetes Obes Metab 2007, 9:233-245.
15. Bohlender J.M., Franke S., Stein G., et al. Advanced glycation end products and the kidney. Am J Physiol 2005, 289:F645-F659.
16. Morimoto K., Ohta K., Yachie A., et al. Cytoprotective role of heme oxygenase (HO)-1 in human kidney with various renal diseases. Kidney Int 2001, 60:1858-1866.
17. Izuhara Y., Nangaku M., Takizawa S., et al. A novel class of advanced glycation inhibitors ameliorates renal and cardiovascular damage in experimental rat models. Nephrol Dial Transplant 2008, 23:497-509.
18. Semba R.D., Fink J.C., Sun K., et al. Carboxymethyl-lysine, an advanced glycation end product, and decline of renal function in older community-dwelling adults. Eur J Nutr 2009, 48:38-44.
19. Chuyen N.V. Toxicity of the AGEs generated from the Maillard reaction: on the relationship of food-AGEs and biological-AGEs. Mol Nutr Food Res 2006, 50:1140-1149.
20. Peppa M., Uribarri J., Cai W., et al. Glycoxidation and inflammation in renal failure patients. Am J Kidney Dis 2004, 43:690-695.
21. Uribarri J., Peppa M., Cai W., et al. Dietary glycotoxins correlate with circulating advanced glycation end product levels in renal failure patients. Am J Kidney Dis 2003, 42:532-538.
22. Semba R.D., Najjar S.S., Sun K., et al. Serum carboxymethyl-lysine, an advanced glycation end product, is associated with increased aortic pulse wave velocity in adults. Am J Hypertens 2009, 22:74-79.
23. Sebekova K., Somoza V. Dietary advanced glycation endproducts (AGEs) and their health effects-PRO. Mol Nutr Food Res 2007, 51:1079-1084.
24. Uribarri J., Cai W., Sandu O., et al. Diet-derived advanced glycation end products are major contributors to the body's AGE pool and induce inflammation in healthy subjects. Ann N Y Acad Sci 2005, 1043:461-466.
25. Guo Z.J., Niu H.X., Hou F.F., et al. Advanced oxidation protein products activate vascular endothelial cells via a RAGE-mediated signaling pathway. Antioxid Redox Signal 2008, 10:1699-1712.
26. Henle T. Dietary advanced glycation end products-a risk to human health? A call for an interdisciplinary debate. Mol Nutr Food Res 2007, 51:1075-1078.
27. Schwenger V., Morath C., Schonfelder K., et al. An oral load of the early glycation compound lactuloselysine fails to accumulate in the serum of uraemic patients. Nephrol Dial Transplant 2006, 21:383-388.
28. KDOQI Clinical Practice Guideline for Nutrition in Children with CKD: 2008 update [Executive summary]. Am J Kidney Dis 2009, 53:S11-S104.
29. Goldberg T., Cai W., Peppa M., et al. Advanced glycoxidation end products in commonly consumed foods. J Am Diet Assoc 2004, 104:1287-1291.
30. KDOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002, 39(2 Suppl 1):S1-S266. National Kidney Foundation.
31. Eckardt K.U., Berns J.S., Rocco M.V., et al. Definition and classification of CKD: the debate should be about patient prognosis-a position statement from KDOQI and KDIGO. Am J Kidney Dis 2009, 53:915-920.
32. Piroddi M., Palmese A., Pilolli F., et al. Plasma nitroproteome of kidney disease patients. Amino Acids 2010 Jul 31, [Epub ahead of print].
33. Floridi A., Trizza V., Paolotti P., et al. Analytical strategy for the assessment of the protein glycation status in uremic patients by high-performance liquid chromatography. J Chromatogr 1999, 846:65-71.
34. Floridi A., Antolini F., Galli F., et al. Daily haemodialysis improves indices of protein glycation. Nephrol Dial Transplant 2002, 17:871-878.
35. Munch G., Keis R., Wessels A., et al. Determination of advanced glycation end products in serum by fluorescence spectroscopy and competitive ELISA. Eur J Clin Chem Clin Biochem 1997, 35:669-677.
36. Wrobel K., Wrobel K., Garay-Sevilla M.E., et al. Novel analytical approach to monitoring advanced glycosylation end products in human serum with on-line spectrophotometric and spectrofluorometric detection in a flow system. Clin Chem 1997, 43:1563-1569.
37. Linden E., Cai W., He J.C., et al. Endothelial dysfunction in patients with chronic kidney disease results from advanced glycation end products (AGE)-mediated inhibition of endothelial nitric oxide synthase through RAGE activation. Clin J Am Soc Nephrol 2008, 3:691-698.
38. Piroddi M., Depunzio I., Calabrese V., et al. Oxidatively-modified and glycated proteins as candidate pro-inflammatory toxins in uremia and dialysis patients. Amino Acids 2007, 32:573-592.
39. Assar S.H., Moloney C., Lima M., et al. Determination of Nepsilon-(carboxymethyl)lysine in food systems by ultra performance liquid chromatography-mass spectrometry. Amino Acids 2009, 36:317-326.
40. De La Maza M.P., Bravo A., Leiva L., et al. Urinary excretion of fluorescent advanced glycation end products (ages) in the elderly. J Nutr Health Aging 2008, 12:222-224.
41. Maza M.P., Bravo A., Leiva L., et al. Fluorescent serum and urinary advanced glycoxidation end-products in non- diabetic subjects. Biol Res 2007, 40:203-212.
42. Roberts M.A., Thomas M.C., Fernando D., et al. Low molecular weight advanced glycation end products predict mortality in asymptomatic patients receiving chronic haemodialysis. Nephrol Dial Transplant 2006, 21:1611-1617.
43. Forbes J.M., Yee L.T., Thallas V., et al. Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis. Diabetes 2004, 53:1813-1823.
44. Thomas M.C., Forbes J.M., MacIsaac R., et al. Low-molecular weight advanced glycation end products: markers of tissue AGE accumulation and more?. Ann N Y Acad Sci 2005, 1043:644-654.
45. Uribarri J., Peppa M., Cai W., et al. Restriction of dietary glycotoxins reduces excessive advanced glycation end products in renal failure patients. J Am Soc Nephrol 2003, 14:728-731.